Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Crucell and DSM Biologics Announce Additional PER.C6(R) Licensing Agreement with MorphoSys
- Leiden, The Netherlands, 17 March 2008 - Dutch biotechnology company Crucell N.V. and DSM Biologics, a business unit of DSM Pharmaceutical Products, today announced that German-based MorphoSys AG has decided to extend the PER.C6® technology licensing agreement entered in September 2004, ...
- Research articles 2008-03-17
- DSM Biologics and Crucell Announce PER.C6(R) Licensing Agreement with Daiichi Sankyo Ltd.
- Sittard/Leiden, The Netherlands, November 16, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a PER.C6® license agreement with Daiichi Sankyo Ltd. (Tokyo Stock Exchange Ticker 4568). This license agreement allows Daiichi Sankyo...
- Research articles 2007-11-16
- DSM Biologics and Crucell Announce PER.C6(R) Licensing Deal With LFB Biotechnologies
- Sittard/Leiden, The Netherlands, July 25, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a non-exclusive PER.C6® research licensing agreement with Paris, France-based LFB Biotechnologies. LFB Biotechnologies will use Crucell's technology...
- Research articles 2007-07-25
- Crucell and DSM Biologics announce PER.C6(R) license agreement with AbGenomics Corporation
- PRESS RELEASE Crucell and DSM Biologics announce PER.C6® license agreement with AbGenomics Corporation Sittard/Leiden, The Netherlands, 11 January 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics today announced that they have signed a PER.C6® research license agreement with...
- Research articles 2007-01-11
- MorphoSys Obtains PER.C6(R) Human Cell Line for Production of Antibody Material in MOR103 Program
- MorphoSys AG (FRANKFURT: MOR) (Prime Standard Segment, TecDAX) today announced the signing of a second PER.C6® license agreement with Dutch biotechnology company Crucell N.V. (Euronext: CRXL) (NASDAQ: CRXL) and contract manufacturer DSM Biologics. This license agreement allows MorphoSys to use the PER.C6® cell line in the production of clinical grade...
- Research articles 2006-08-17
- Crucell and DSM Biologics Announce PER.C6(R) Licensing Agreement with UCB
- Leiden/Sittard, The Netherlands, March 14, 2006 - Dutch biotechnology company Crucell N.V. (Euronext and NASDAQ: CRXL; Swiss Exchange: SW CRX) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement with global biopharmaceutical leader...
- Research articles 2006-03-14
- Crucell and DSM further strengthen and expand the development of PER.C6(R) Protein and Monoclonal Antibody Licensing Business
- Leiden/Heerlen, The Netherlands, December 20, 2005 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and DSM Biologics, a business unit of DSM Pharmaceutical Products a business group of Royal DSM NV announced today that they will...
- Research articles 2005-12-20
- Crucell and DSM further strengthen and expand the development of PER.C6(R) Protein and Monoclonal Antibody Licensing Business
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and DSM Biologics, a business unit of DSM Pharmaceutical Products a business group of Royal DSM NV announced today that they will strengthen and expand the development of the PER.C6® protein and monoclonal antibody licensing business. The two companies will create an...
- Research articles 2005-12-20
- Crucell/Dsm Sign Licensing Pact With Mitsubishi Pharma
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) has announced that allied contract manufacturer DSM Biologics has signed a PER.C6 research license agreement with the Japanese pharmaceutical company Mitsubishi Pharma Corporation. This license agreement allows Mitsubishi to use the PER.C6 cell line for production of certain recombinant therapeutic proteins. This...
- Research articles 2005-05-01
- Crucell Licenses Per.C6 Technology To Glaxosmithkline
- Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) and allied contract manufacturer DSM Biologics have announced that Crucell has signed a PER.C6 research license agreement with GlaxoSmithKline. This license allows GlaxoSmithKline to use Crucell's PER.C6 technology in research and preclinical development related to its portfolio of recombinant monoclonal antibody products....
- Research articles 2004-10-01
Additional Resources
- Genmab A/S signs commercial production agreement for HuMax-CD4 with DSM Biologics
- NORDIC BUSINESS REPORT-1 June 2004-Genmab A/S signs commercial production agreement for HuMax-CD4 with DSM BiologicsC1994-2004 M2 COMMUNICATIONS LTD http://www.m2.com The Danish biotechnology company Genmab A/S said on Tuesday (1 June) that it had signed a commercial production agreement regarding its antibody product HuMax-CD4 with the Dutch-Canadian company DSM Biologics....
- Research articles 2004-06-01
- DSM Biologics and Crucell Announce PER.C6(R) Licensing Agreement with Medarex Inc.
- Sittard/Leiden, The Netherlands, December 18, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced a PER.C6® license agreement with biopharmaceutical company Medarex, Inc. This license agreement allows Medarex to use the PER.C6® production...
- Research articles 2007-12-18
- DSM Biologics and Crucell Announce PER.C6(R) Licensing Agreement with Biotecnol SA for Antibody Production
- Sittard/Leiden, The Netherlands, and Oeiras, Portugal January 5, 2006 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology partner Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that they have signed a PER.C6® license agreement with pioneering and leading Portuguese biotechnology company, Biotecnol SA,...
- Research articles 2007-01-05
- DSM Biologics and Crucell Announce PER.C6(R) Licensing Deal with Taiwanese Development Center for Biotechnology
- Sittard/Leiden, The Netherlands, March 26, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that they have signed a non-exclusive PER.C6® research licensing deal with Taipei, Taiwan-headquartered Development Center for Biotechnology DCB. DCB will...
- Research articles 2007-03-26
- DSM Biologics and Crucell Announce PER.C6(R) Technology Licensing Agreement with Recepta Biopharma S.A.
- Sittard/Leiden, The Netherlands, November 2, 2007 - DSM Biologics, a business unit of DSM Pharmaceutical Products and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that they have signed a non-exclusive PER.C6®...
- Research articles 2007-11-02
- DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
- DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that Hungary-based Gedeon Richter Plc. signed a commercial license agreement allowing Gedeon Richter to develop and ...
- Research articles 2008-11-25
- Crucell and DSM Biologics Announce Invitrogen as First Partner in PER.C6(R) Vendor Network
- Leiden, The Netherlands, July 10, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) and technology partner DSM Biologics have announced today that Invitrogen, a leading life...
- Research articles 2006-07-10
- Crucell and DSM Biologics Announce PER.C6(R) Licensing Agreement with UMN Pharma
- Leiden/Sittard, The Netherlands, March 9, 2006 - Dutch biotechnology company Crucell N.V. (Euronext and NASDAQ: CRXL; Swiss Exchange: SW CRX) and allied contract manufacturer DSM Biologics announced today that they have signed a PER.C6® research license agreement with Japanese...
- Research articles 2006-03-09
- DSM Biologics
- DSM Biologics of Montreal, Canada, has formed a partnership with the Japanese company Asahi Glass to jointly explore the Japanese market for innovative biopharmaceuticals and the potential demand for contract manufacturing in the sector.
- Research articles 2000-06-12
- DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
- DSM Biologics and Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that they have entered into an agreement with Bioceros B.V. of Utrecht, The Netherlands to join their Vendor Network. Under the terms ...
- Research articles 2009-02-10
- << Previous
- page 1 of 1
- Next >>
